Department of Pediatrics
Jun. 4, 2020—The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.
Apr. 30, 2020—Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody "cocktails" to counter viral infection.
Apr. 21, 2020—Parents of children with autism spectrum disorders benefited from the addition of mindfulness-based stress reduction to parent-implemented behavioral interventions.
Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments
Apr. 9, 2020—Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Apr. 6, 2020—Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.
Oct. 3, 2019—For patients in pediatric intensive care who are at high risk for acute kidney injury (AKI), giving clinicians automated decision support during the electronic order entry process increased the rate of blood testing for AKI by 9%.
Sep. 25, 2019—An observational study using medical record information from nearly 50,000 U.S. military veterans sheds new light on which drugs are best for patients with Type 2 diabetes and one of its common complications, kidney disease.